$TCRX

TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated dat

Amgen (NASDAQ: AMGN) terminated its collaboration with TScan Therapeutics (NASDAQ: TCRX), ending over USD 500 million in potential milestone payments for TScan. The agreement, effective November 10, 2026, focused on TScan's T-cell receptor discovery platform for Crohn's disease. TScan reported progress in its Phase III ALLOHA-2 trial for TSC-101, a therapy for hematologic malignancies, with topline data expected mid-2028.

Amgen will terminate its research collaboration and license agreement with TScan Therapeutics, according to an SEC filing. The companies had been working together on developing novel cancer therapies.

TScan Therapeutics (TCRX) announced that Amgen has terminated their Research Collaboration and License Agreement for Crohn's disease, effective November 10, 2026. TScan will not face penalties but will lose potential $500M+ in milestones and royalties. The company received a $30M upfront payment in 2023.

TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. On August 12, 2026, TScan Therapeutics, Inc. (the “ Company ”) received notice from Amgen Inc. (“ Amgen ”) of its election to terminate, in its entirety, the Research Collaboration and License Agreement, dated as of May 8,

TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal c

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.00% and -21.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +60.80% and +50.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for ...

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026